JSM 2011 Online Program
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Activity Details
|
|
|||
| 423 | Tue, 8/2/2011, 2:00 PM - 3:50 PM | CC-Hall D | |
| Contributed Oral Poster Presentations: Biopharmaceutical Section — Contributed Poster Presentations | |||
| Biopharmaceutical Section | |||
| Chair(s): Benmei Liu, National Cancer Institute | |||
| 01: | A Joint Model for Tumor Burden and Progression-Free Survival — Aparna B. Anderson, Bristol-Myers Squibb ; Ye Shen, Yale University School of Public Health ; Ritwik Sinha, Hewlett Packard Laboratories India | ||
| 02: | Reinforcement Learning Strategies for Clinical Trials in Non-Small Cell Lung Cancer — Yufan Zhao, Amgen Inc. | ||
| 03: | Evaluation of Power and Type I Error on Different Statistical Methods Analyzing Hypoglycemia Data Using Bootstrap Simulation — Honghua Jiang, Eli Lilly and Company ; William Huster, Eli Lilly and Company ; Xiao Ni , Eli Lilly and Company | ||
| 04: | Estimating Controlled Direct Effects for Time-Varying Treatments Using Structural Nested Mean Models — Tomohiro Shinozaki, The University of Tokyo ; Yutaka Matsuyama, The University of Tokyo ; Yasuo Ohashi, The University of Tokyo | ||
| 05: | The Ratio of Median or Mean Change Scores for Treatment Comparisons — Joseph T. Wang, Pfizer Inc. ; Kelly H. Zou, Pfizer Inc. ; Martin Ove Carlsson, Pfizer Inc. | ||
| 06: | Sample Size Calculations in Clinical Trials with Binary Data: Theoretical and Practical Issues — Arminda Siqueira, Universidade Federal de Minas Gerais | ||
| 07: | Predict the Probability of Final Trial Success in Interim Analysis — Rujun Teng, Merck & Co., Inc. ; Kaifeng Lu, Forest Laboratories, Inc. | ||
| 08: | Using Z-Prime Factor as Quantitative Measure of In Vivo PD Assay Quality — Winnie Weng, Amgen Inc. ; Guang Chen, Amgen Inc. ; Margaret Weidner, Amgen Inc. ; Kathy Keegan, Amgen Inc. ; Christophe Queva, Amgen Inc. | ||
| 09: | Analysis of GEF-Mediated Nucleotide Exchange Assay Experiments — Qinghua Song, Genentech Inc. ; Lindsay Garrenton, Genentech Inc. ; Imola Fodor, Genentech Inc. ; Guowei Fang, Genentech Inc. ; Peter Jackson, Genentech Inc. | ||
| 10: | Using Reinforcement Learning Strategies to Discover the Optimal Treatment for Advanced Colorectal Cancer Patients — Zheng Ren, The University of North Carolina at Chapel Hill ; Michael R. Kosorok, The University of North Carolina at Chapel Hill | ||
| 11: | A Distribution-Free Bayesian Method for Estimating the Probability of Response in Combination Drug Tests — John W. Seaman III, Alcon Laboratories, Inc. ; John W. Seaman Jr., Baylor University ; James Stamey, Baylor University | ||
| 12: | An Application of Group Sequential Method for Demonstration of Efficacy in Diagnostic Imaging Development — Gajanan Bhat, Lantheus Medical Imaging, Inc. ; Jeffrey Joseph, Omnicare Clinical Research, Inc. ; Dana Washburn, Lantheus Medical Imaging, Inc. | ||
| 13: | Study Design of a Drug-Drug Interaction Trial Using Group Sequential Methods — Wei Zhang, Eli Lilly and Company | ||
| 14: | A Comparison of Methods for Adjusting for the Baseline Measure — Martin Ove Carlsson, Pfizer Inc. ; Kelly H. Zou, Pfizer Inc. ; Ching-Ray Yu, Pfizer Inc. ; Franklin W. Sun, Pfizer Inc. | ||
| 15: | Direct Cost of Schizophrenia in Quebec, Canada: An Incidence-Based Microsimulation Monte Carlo Markov Model — Alice Dragomir, University of Montreal ; Jean-Eric Tarride, McMaster University ; Ridha Joober, McGill University ; Guy Rouleau, University of Montreal ; Sylvie Perreault, University of Montreal | ||
| 16: | Evaluation of Power of Different Cox Proportional Hazards Models Incorporating Stratification Factors — Moumita Sinha, Biocon Ltd. ; Shanshan Ding, University of Minnesota | ||
| 17: | Stratified Two-Sample Tests on the Change Scores When the Outcomes Are Correlated Between Baseline and Post-Treatment: A Simulation Study Using Bivariate Data — Ching-Ray Yu, Pfizer Inc. ; Martin Ove Carlsson, Pfizer Inc. ; Kelly H. Zou, Pfizer Inc. | ||
| 18: | Leveraging Baseline Information to Improve Inference in Adaptive Randomized Experiments with Small Sample Size — Po-Han Brian Chen, The Johns Hopkins University ; Rosenblum Michael, The Johns Hopkins University | ||
| 19: | Evaluating Oncology Phase I Dose-Finding Study Designs — Lindsey Lian, PPD ; Hui Liu, PPD ; Jenny Huang, PPD | ||
| 20: | The VACS Risk Index Responds to Treatment Interventions and Is Highly Correlated with and Predictive of Mortality Events in the Optima Study — Katherine Anne Kirkwood, VA Cooperative Studies Program ; Tassos Kyriakides, VA Cooperative Studies Program ; Sheldon T. Brown, James J. Peters VA Medical Center ; Amy C. Justice, VA Connecticut Healthcare System, West Haven ; Mark Holodniy, VA Palo Alto Healthcare System ; Janet Tate, VA Connecticut Healthcare System, West Haven ; Joseph Goulet, VA Connecticut Healthcare System, West Haven | ||
| 21: | Subgroup Discovery Showing Maximum Difference Between Treatment and Control Using Modified Patient Rule Induction Method (M-PRIM) — Daniel Parks, GlaxoSmithKline ; Xiwu Lin, GlaxoSmithKline ; Kwan Lee, GlaxoSmithKline | ||
| 22: | A Phase II/III Randomized Clinical Trial Design with Sequential Decision Rule Based on Multiple Primary Endpoints — Qian Shi, Mayo Clinic ; Daniel J. Sargent, Mayo Clinic | ||
| 23: | One-sided Upper Tolerance Limits for Longitudinal Data — Judy X. Li, U.S. Food and Drug Administration ; Oscar Chiesa, U.S. Food and Drug Administration ; Min Zhu, SAS Institute Inc. | ||
| 24: | Evaluation of Different Numbers of Dilution Serials of Biological Samples Tested in Cell-Based Functional Assays — Liping Song, Merck & Co., Inc. ; Robert Capen, Merck & Co., Inc. | ||
| 25: | Quantification of Impact of Safety Monitoring on Type I Error and Power of Efficacy Analysis in Phase III Group Sequential Clinical Trial — Yanqiu Weng, Medical University of South Carolina ; Wenle Zhao, Medical University of South Carolina ; Yuko Palesch, Medical University of South Carolina | ||
2011 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.